Barriers and facilitators of exploiting the potential of value-added medicines

References

• Cameron A, Mantel-Teeuwisse AK, Leufkens HG, et al. Switching from originator brand medicines to generic equivalents in selected developing countries: how much could be saved? Value Health. 2012;15(5):664–673.
   PubMed Web of Science ®Google Scholar
• Wouters OJ, Kanavos PG, McKee M. Comparing generic drug markets in Europe and the United States: prices, volumes, and spending. Milbank Q. 2017;95(3):554–601.
   PubMed Web of Science ®Google Scholar
• Kaló Z, Holtorf AP, Alfonso-Cristancho R, et al. Need for multicriteria evaluation of generic drug policies. Value Health. 2015;18:346–351.
   PubMed Web of Science ®Google Scholar
• Dylst P, Vulto A, Simoens S. Societal value of generic medicines beyond cost-saving through reduced prices. Expert Rev Pharmacoecon Outcomes Res. 2015;15(4):701–711.
   PubMed Web of Science ®Google Scholar
• Medicines for Europe – Value added medicines [Internet]. Brussels, Belgium; [ cited 2019 Aug 20]. Available from: https://www.medicinesforeurope.com/value-added-medicines/did-you-know/
   Google Scholar
• DiMasi JA, Grabowski HG, Hansen RW. Innovation in the pharmaceutical industry: new estimates of R&D costs. J Health Econ. 2016;47:20–33.
   PubMed Web of Science ®Google Scholar
• Klein MB. Hepatitis C virus elimination: time for disruptive innovation. J Int AIDS Soc. 2019;22:7.
   Web of Science ®Google Scholar
• Alt S, Helmstädter A. Market entry, power, pharmacokinetics: what makes a successful drug innovation? Drug Discov Today. 2018;23(2):208–212.
   PubMed Web of Science ®Google Scholar
• Medicines for Europe – Value added medicines [Internet]. Brussels, Belgium; [ cited 2020 Feb 15]. Available from: https://www.medicinesforeurope.com/wp-content/uploads/2019/04/IQVIA-MFE_Case-Studies-for-VAMs_Final-Word-Document_vUpdate2019-v3.0.pdf
   Google Scholar
• Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005;353(5):487–497.
   PubMed Web of Science ®Google Scholar
• Agh T, Inotai A, Meszaros A. Factors associated with medication adherence in patients with chronic obstructive pulmonary disease. Respiration. 2011;82(4):328–334.
   PubMed Web of Science ®Google Scholar
• van der Palen J, Cerveri I, Roche N, et al. DuoResp® Spiromax® adherence, satisfaction and ease of use: findings from a multi-country observational study in patients with asthma and COPD in Europe (SPRINT). J Asthma. 2019. DOI:10.1080/02770903.2019.1634097
   Web of Science ®Google Scholar
• Papazisis G, Siafis S. The added value of liquid antipsychotics: the case of quetiapine. Curr Clin Pharmacol. 2019;14(2):101–107.
   PubMed Web of Science ®Google Scholar
• Madhavan A, LaGorio LA, Crary MA, et al. Prevalence of and risk factors for dysphagia in the community dwelling elderly: a systematic review. J Nutr Health Aging. 2016;20(8):806–815.
   PubMed Web of Science ®Google Scholar
• Bushardt RL, Massey EB, Simpson TW, et al. Polypharmacy: misleading, but manageable. Clin Interv Aging. 2008;3(2):383.
   PubMed Web of Science ®Google Scholar
• Rieckert A, Trampisch US, Klaaßen-Mielke R, et al. Polypharmacy in older patients with chronic diseases: a cross-sectional analysis of factors associated with excessive polypharmacy. BMC Fam Pract. 2018;19(1):113.
   PubMed Web of Science ®Google Scholar
• Wimmer BC, Cross AJ, Jokanovic N, et al. Clinical outcomes associated with medication regimen complexity in older people: a systematic review. J Am Geriatr Soc. 2017;65(4):747–753.
   PubMed Web of Science ®Google Scholar
• Bramlage P, März W, Westermann D, et al. Management verschiedener kardiovaskulärer Risikofaktoren mit einem Kombinationspräparat („Polypill “). Herz. 2018;43(3):246–257.
   PubMedGoogle Scholar
• Talevi A, Bellera CL. Challenges and opportunities with drug repurposing: finding strategies to find alternative uses of therapeutics. Expert Opin Drug Discov. 2020;15(4):97–401.
   PubMed Web of Science ®Google Scholar
• Vargesson N. Thalidomide-induced teratogenesis: history and mechanisms. Birth Defects Res Part C. 2015;105(2):140–156.
   PubMedGoogle Scholar
• World Health Organization – WHO – Leprosy elimination [Internet]. Geneva, Switzerland; [ cited 2020 Feb 15]. Available from: https://www.who.int/lep/research/thalidomide/en/
   Google Scholar
• Palumbo A, Bringhen S, Caravita T, et al. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial. Lancet. 2006;367(9513):825–831.
   PubMed Web of Science ®Google Scholar
• The National Institute for Health and Care Excellence - NICE guidance [Internet]. London, United Kingdom; [ cited 2019 Sept 29]. Available from: https://www.nice.org.uk/guidance/ta228/documents/multiple-myeloma-first-line-bortezomib-and-thalidomide-final-appraisal-determination3
   Google Scholar
• Bochenek T, Abilova V, Alkan A, et al. Systemic measures and legislative and organizational frameworks aimed at preventing or mitigating drug shortages in 28 European and Western Asian countries. Front Pharmacol. 2018;8:942.
   PubMed Web of Science ®Google Scholar
• Toumi M, Rémuzat C. Value added medicines: what value repurposed medicines might bring to society? J Mark Access Health Policy. 2017;5(1):1264717.
   PubMedGoogle Scholar
• American Society of Health-System Pharmacists (ASHP) – Drug shortage statistics [Internet]. Bethesda, Maryland, USA; [ cited 2019 Aug 18]. Available from: https://www.ashp.org/Drug-Shortages/Shortage-Resources/Drug-Shortages-Statistics
   Google Scholar
• Acosta A, Vanegas EP, Rovira J, et al. Medicine shortages: gaps between countries and global perspectives. Front Pharmacol. 2019;10:763.
   PubMed Web of Science ®Google Scholar
• Iyengar S, Hedman L, Forte G, et al. Medicine shortages: a commentary on causes and mitigation strategies. BMC Med. 2016;14(1):124.
   PubMedGoogle Scholar
• Stegemann S, Klebovich I, Antal I, et al. Improved therapeutic entities derived from known generics as an unexplored source of innovative drug products. Eur J Pharm Sci. 2011;44(4):447–454.
   PubMed Web of Science ®Google Scholar
• Langedijk J, Mantel-Teeuwisse AK, Slijkerman DS, et al. Drug repositioning and repurposing: terminology and definitions in literature. Drug Discov Today. 2015;20(8):1027–1034.
   PubMed Web of Science ®Google Scholar
• Ashburn TT, Thor KB. Drug repositioning: identifying and developing new uses for existing drugs. Nat Rev Drug Discov. 2004;3(8):673.
   PubMed Web of Science ®Google Scholar
• Oprea TI, Bauman JE, Bologa CG, et al. Drug repurposing from an academic perspective. Drug Discov Today. 2011;8(3–4):61–69.
   Google Scholar
• Reed MD. The rescue and repurposing of pharmaceuticals: augmenting the drug development paradigm. J Pediatr Pharmacol Ther. 2016 Jan-Feb;21(1):4–6.
   PubMedGoogle Scholar
• Rémuzat C, Toumi M. Value added medicines: the need to establish one common terminology for repurposed medicines. ISPOR 19th Annual European Congress; 2016 Oct 29 –Nov 02; Vienna, Austria; 2016. p. PHP139.
   Google Scholar
• Inotai A, Ágh T, Karpenko AW, et al. Behind the subcutaneous trastuzumab hype: evaluation of benefits and their transferability to central Eastern European Countries. Expert Rev Pharmacoecon Outcomes Res. 2019;19(2):105–113.
   PubMed Web of Science ®Google Scholar
• Bangalee V, Suleman F. Pseudo-generics in South Africa: a price comparison. Value Health Reg Issues. 2019;19:87–91.
   PubMedGoogle Scholar
• Editorial. Generic bashing: effective but illegal. Rev Prescrire. 2013;33(360):779.
   Google Scholar
• Goodman B, Wilcock M, Martin A, et al. Generic pregabalin: current situation and implications for health authorities, generics and biosimilars manufacturers in the future. GaBI J. 2015;4(3):125–135.
   Google Scholar
• Institute for Health Metrics and Evaluation (IHME). Findings from the global burden of disease study 2017. Seattle, WA: IHME, 2018; [cited 2019 Sept 27] Available from: http://www.healthdata.org/sites/default/files/files/policy_report/2019/GBD_2017_Booklet.pdf
   Google Scholar
• Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines. J Am Coll Cardiol. 2018;71(19):e127–e248.
   PubMed Web of Science ®Google Scholar
• The National Institute for Health and Care Excellence - NICE guideline [Internet]. London, United Kingdom; [ cited 2019 Sept 29]. Available from: https://www.nice.org.uk/guidance/ng28/resources/type-2-diabetes-in-adults-management-pdf-1837338615493
   Google Scholar
• Remington G, Addington D, Honer W, et al. Guidelines for the pharmacotherapy of schizophrenia in adults. Can J Psychiatry. 2017;62(9):604–616.
   PubMed Web of Science ®Google Scholar
• Charoo NA, Ali AA, Buha SK, et al. Lesson learnt from recall of valsartan and other angiotensin II receptor blocker drugs containing NDMA and NDEA impurities. AAPS PharmSciTech. 2019;20(5):166.
   PubMed Web of Science ®Google Scholar
• Al-Kindi SG, Oliveira GH. Abrupt increase in reporting of neoplasms associated with valsartan after medication recall. Circulation. 2019;12(7):e005536.
   PubMed Web of Science ®Google Scholar
• Snodin DJ, Elder DP. Short commentary on NDMA (N-nitrosodimethylamine) contamination of valsartan products. Regul Toxicol Pharmacol. 2019;103:325–329.
   PubMed Web of Science ®Google Scholar
• Barei F. Where does the value of ‘value-added’pharmaceuticals come from? GaBI J. 2016;5(4):171–173.
   Google Scholar
• Acosta A, Ciapponi A, Aaserud M, et al. Pharmaceutical policies: effects of reference pricing, other pricing, and purchasing policies. Cochrane Database Syst Rev. 2014;10:CD005979.
   Google Scholar
• Maniadakis N, Holtorf AP, Corrêa JO, et al. Shaping pharmaceutical tenders for effectiveness and sustainability in countries with expanding healthcare coverage. Appl Health Econ Health Policy. 2018;16(5):591–607.
   PubMed Web of Science ®Google Scholar
• Inotai A, Brixner D, Maniadakis N, et al., Development of multi-criteria decision analysis (MCDA) framework for off-patent pharmaceuticals–an application on improving tender decision making in Indonesia. BMC Health Serv Res. 2018;18(1): 1003.
   PubMedGoogle Scholar
• Abdullah AH, Holtorf AP, Al-Hussaini M, et al. Stakeholder driven development of a multi-criteria decision analysis tool for purchasing off-patent pharmaceuticals in Kuwait. J Pharm Policy Pract. 2019;12(1):9.
   PubMed Web of Science ®Google Scholar
• Assawamakin A, Holtorf AP, Maniadakis N. Weighing price and performance for decisions for multisource pharmaceutical bidding in public hospitals in Thailand. In: Evaluation of health programs. IntechOpen; 2019.
   Google Scholar